Press Releases Ascelia Pharma AB

Equities

ACE

SE0010573113

Market Closed - Nasdaq Stockholm Other stock markets 12:00:00 2024-07-05 pm EDT			5-day change	1st Jan Change
9.23 ^SEK	+0.33%		+12.01%	+173.89%

Jun. 17	Transcript : Ascelia Pharma AB - Special Call
May. 21	Transcript : Ascelia Pharma AB, Q1 2024 Earnings Call, May 21, 2024

Press Releases

Unlock all the news on all businesses: Never miss an investment opportunity again!

100% Free Registration

Ascelia Pharma - Time for take-off	May. 20	AQ
Quarterly Report Q1: Primary Endpoint Met with Strong Headline Results in Orviglance Phase 3 Study	May. 16	AQ
Welcome to Ascelia Pharma Investor Update: Bringing Orviglance to Patients	May. 07	AQ
Bulletin from the Annual General Meeting in Ascelia Pharma AB on 6 May 2024	May. 06	AQ
Ascelia Pharma Successfully Meets Primary Endpoint with Strong Headline Results in Orviglance Phase 3 Study	May. 02	AQ
Ascelia Pharma Draws Down SEK 15 Million Second Tranche Under Existing Loan Facility	Apr. 18	AQ
Ascelia Pharma Reports SPARKLE Image Reading Completion and Expects Headline Results First Half of May 2024	Apr. 10	AQ
Annual Report 2023: Solid Progress with Orviglance Phase 3 Patient Recruitment Completed and Headline Results Expected by May 2024	Apr. 08	AQ
Notice of Annual General Meeting in Ascelia Pharma AB	Mar. 27	AQ
Ascelia Pharma Q4 2023 - On track with easing financial pressure	Feb. 12	AQ
Q4 and Full Year Report 2023: Strengthened Financial Position Ahead of SPARKLE Phase 3 Study Headline Results in May	Feb. 09	AQ
Ascelia Pharma Secures Financing of up to SEK 35 Million	Feb. 04	AQ
Orviglance Review Article Published in Investigative Radiology	Jan. 24	AQ
Nomination Committee Appointed for AGM 2024 in Ascelia Pharma AB	Jan. 24	AQ
Ascelia Pharma Announces Start of Image Reading Phase and Re-confirms Phase 3 SPARKLE Results by May 2024	Dec. 07	AQ
Change in Number of Shares and Votes in Ascelia Pharma AB	Nov. 30	AQ
Bulletin from the Extraordinary General Meeting in Ascelia Pharma AB on 13 November 2023	Nov. 13	AQ
Ascelia Pharma resolves on conversion of series C shares into ordinary shares for delivery to participants in incentive program	Nov. 09	AQ
QUARTERLY REPORT Q3 2023: Re-evaluation of SPARKLE Phase 3 Study Images Progresses According to Plan	Nov. 08	AQ
OptiCept Technologies recruits a new CFO	23-10-20	AQ

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Press Releases Ascelia Pharma AB

Equities

ACE

SE0010573113

Press Releases

Filters